Drug intelligence / Profile preview

Zaizao Shengxue Jiaonang

Development stage: Unknown
Lead developer: Lei Yun Shang
Administration: Oral

Overview

Zaizao Shengxue Jiaonang is a Traditional Chinese Medicine (TCM) capsule developed and manufactured by Liaoyuan Yulongyadong Pharmaceutical. It is formulated to treat hematological disorders by tonifying the liver and kidney and replenishing qi and blood. The drug is primarily indicated for conditions such as aplastic anemia, myelodysplastic syndrome (MDS), leukopenia, and thrombocytopenia. Clinical studies, including those conducted at Dongzhimen Hospital, have evaluated its efficacy in improving peripheral hemograms and alleviating symptoms associated with qi and blood deficiency in MDS patients.

Brand names: Zaizao Shengxue Jiaonang
Other names: Zaizao Shengxue CapsuleZaizaoshengxue capsule

Beyond the preview

Go deeper on Zaizao Shengxue Jiaonang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zaizao Shengxue Jiaonang.

Explore the full profile